4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Sales of some drugs/vaccines/products were hurt by business disruption due to the coronavirus pandemic in the first quarter of 2021. Most companies expect the pandemic to continue to have some negative impact on sales in the second quarter though trends are expected to be better as economies re-open and vaccinations continue in full swing. Meanwhile, successful innovation resulting in new drug/product approvals, important advances in clinical studies, and strategic collaborations with strong partners have kept companies like Xencor (XNCR), Organogenesis Holdings (ORGO), Cumberland Pharmaceuticals (CPIX) and Acer Therapeutics (ACER) afloat.
afloat.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Xencor, Inc. (XNCR) : Free Stock Analysis Report
 
Organogenesis Holdings Inc. (ORGO) : Free Stock Analysis Report
 
Cumberland Pharmaceuticals Inc. (CPIX) : Free Stock Analysis Report
 
Opexa Therapeutics, Inc. (ACER) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research